NCT00478725View on ClinicalTrials.gov

Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034

PHASE1CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

July 18, 2007

Primary Completion Date

July 1, 2008

Study Completion Date

July 1, 2008

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

GW786034, oral

oral, 800 mg

DRUG

GW786034, IV

IV, 5 mg

DRUG

GW786034, radiolabeled oral

oral, 400 mg radiolabeled

Trial Locations (2)

37203

GSK Investigational Site, Nashville

55404

GSK Investigational Site, Minneapolis

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY